HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer.

Abstract
A randomized double-blind study with a 3-yr follow-up comparing the two arms "orchiectomy + Anandron (300 mg)" vs "orchiectomy + placebo" in 125 patients with stage D prostate cancer has confirmed the beneficial effects of the combined Anandron therapy on subjective parameters and on the best objective response (NPCP criteria), although these effects were not statistically significant, but failed to detect any improvement in time-to-disease progression or survival. Comparison with the results of other trials emphasizes the urgent need to establish suitable prognostic factors by further clinical research before evaluating the benefits of individual drugs.
AuthorsM Namer, J Toubol, A Caty, J E Couette, J Douchez, P Kerbrat, J P Droz
JournalThe Journal of steroid biochemistry and molecular biology (J Steroid Biochem Mol Biol) Vol. 37 Issue 6 Pg. 909-15 (Dec 20 1990) ISSN: 0960-0760 [Print] England
PMID2285605 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Imidazoles
  • Imidazolidines
  • nilutamide
Topics
  • Aged
  • Aged, 80 and over
  • Double-Blind Method
  • Follow-Up Studies
  • Humans
  • Imidazoles (therapeutic use)
  • Imidazolidines
  • Male
  • Middle Aged
  • Orchiectomy
  • Prostatic Neoplasms (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: